{"filing":{"accession_number":"0001628280-26-042176","cik":"0002023658","ticker":"BCAX","company_name":"Bicara Therapeutics Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"bcax-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026042176/bcax-20260609.htm"},"events":[{"id":5776,"run_id":5063,"accession_number":"0001628280-26-042176","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Bicara Therapeutics' June 9, 2026 annual meeting, filed under Item 5.07. The filing reports final voting tallies for two proposals: election of class II directors (Christopher Bowden and Carolyn Ng) and ratification of KPMG LLP as independent auditor. Both proposals passed with overwhelming majorities (88.4% and 99.98% approval respectively), and the disclosure includes attendance metrics (85.25% quorum) and detailed vote breakdowns.","company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5815,"accession_number":"0001628280-26-042176","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Bicara Therapeutics' June 9, 2026 annual meeting, filed under Item 5.07. The filing reports final voting tallies for two proposals: election of class II directors (Christopher Bowden and Carolyn Ng) and ratification of KPMG LLP as independent auditor. Both proposals passed with overwhelming majorities (88.4% and 99.98% approval respectively), and the disclosure includes attendance metrics (85.25% quorum) and detailed vote breakdowns.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:27.292130+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5815,"accession_number":"0001628280-26-042176","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Bicara Therapeutics' June 9, 2026 annual meeting, filed under Item 5.07. The filing reports final voting tallies for two proposals: election of class II directors (Christopher Bowden and Carolyn Ng) and ratification of KPMG LLP as independent auditor. Both proposals passed with overwhelming majorities (88.4% and 99.98% approval respectively), and the disclosure includes attendance metrics (85.25% quorum) and detailed vote breakdowns.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:27.292130+00:00","company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","filing_date":"2026-06-10"}]}